Molecular mechanisms in DYT-PRKRA: pathways regulated by PKR activator protein PACT

Abstract

Dystonia-PRKRA (DYT-PRKRA), previously termed dystonia 16 (DYT16), is a movement disorder which currently has very limited treatments available and no cure. To develop effective therapeutic options, it is essential to characterize the underlying pathophysiology and identify potential drug targets. This review summarizes the recent studies that shed light on the molecular mechanisms involved in DYT-PRKRA pathogenesis. PRKRA gene encodes for the protein PACT (Protein Activator of the Protein Kinase R) and individuals with DYT-PRKRA mutations develop early-onset generalized dystonia. While the precise mechanisms linking PRKRA mutations to neuronal etiology of dystonia remain incompletely understood, recent research indicates that such mutations cause dysregulation of signaling pathways involved in cellular stress response as well as in production of antiviral cytokines interferons (IFNs). This review focuses on the effect of DYT-PRKRA mutations on the known cellular functions of PACT.

Introduction

Dystonia is a neurological movement disorder characterized by involuntary and intermittent or sustained muscle contractions leading to abnormal, repetitive twisting movements and/or abnormal postures [1]. This condition can have diverse manifestations, affecting specific muscle groups or the entire body, leading to a loss of coordinated movements [2]. It is a highly heterogeneous neurological movement disorder both clinically and genetically and in recent years many important genetic as well as molecular insights have suggested several therapeutic drug targets [3]. However, the translation of such knowledge into new therapies is yet to emerge as developing effective drugs involves in-depth research on identified genes, requiring significant resources and time. The genetically inherited monogenic dystonia manifests in various forms; each one characterized by distinct features [2]. Focal Dystonia targets specific body regions, such as the neck (cervical dystonia), eyelids (blepharospasm), hand (writer’s cramp), or vocal cords (spasmodic dysphonia). In contrast, segmental dystonia impacts adjacent body parts, potentially combining areas like cervical and oromandibular dystonia. Generalized dystonia extends its reach across multiple or all body parts, exerting a notable influence on both upper and lower extremities, thereby affecting mobility and posture. Hemidystonia uniquely affects one side of the body, inducing muscle contractions and abnormal movements. Multifocal dystonia involves multiple non-contiguous body parts, presenting a diverse clinical picture. Task-Specific dystonia emerges during specific activities, such as musician’s dystonia or writer’s cramp and paroxysmal dystonia is marked by intermittent episodes of dystonia. This spectrum highlights the complex nature of dystonia and the various ways it can manifest in affected individuals.

DYT-PRKRA is caused by mutations in the PRKRA gene (OMIM: 612067), which encodes the protein activator (PACT) of the interferon-induced protein kinase PKR [4]. The characteristics of DYT-PRKRA patients have been summarized in a recent review [2] and in Table 1. The vast majority of PRKRA mutation carriers show generalized dystonia, but some patients with segmental/multifocal dystonia or focal dystonia have been noted. DYT-PRKRA most often starts in the limbs (upper > lower), sometimes cervical or laryngeal, and rarely in the neck. Tremor was reported in some patients, myoclonus in none of them, and Parkinsonism was described in about half the patients. Information on psychiatric signs and other nonmotor symptoms is rarely indicated but cognitive impairment and global developmental delay especially after a childhood febrile illness has been noted [5–9]. The age of onset was reported to be early during childhood in most cases but later onset during adulthood has been observed indicating environmental or other modifying genetic factors. Abnormalities and degeneration in striatal region have been noted in a few patients but this information was not available for most patients [6–8]. Investigations into structural brain changes in DYT-PRKRA patients remain ongoing and a possible neurodegenerative classification of DYT-PRKRA can be considered after such analysis in additional DYT-PRKRA patients. The globus pallidus internus (GPi) region has evolved as a potential target for deep brain stimulation (DBS) and GPi-DBS is used as a therapeutic intervention for several types of dystonia [10]. However, GPi-DBS has not shown much benefit in several DYT-PRKRA patients and other established treatments including botulinum toxin injections, baclofen, and benzodiazepines were shown not to be beneficial [2]. In one case, DYT-PRKRA was reported to improve after thiamine therapy [11], but this has not been reported in other cases. Thus, understanding the molecular mechanisms responsible for DYT-PRKRA is a priority of significant importance for developing novel and effective treatment options.

Functional domains of PACT and DYT-PRKRA mutations

The most studied function of PACT is its role in catalytic activation of the interferon-induced protein kinase PKR (protein kinase, RNA activated) via a direct interaction. PKR (aka EIF2AK2) is a serine threonine protein kinase that was originally discovered in the context of antiviral innate immune response [12]. PKR is ubiquitously expressed at low constitutive levels and its kinase activity stays latent until bound by an activator. Upon binding to one of its two activators: i) double-stranded (ds) RNA [13], or ii) protein activator PACT [4] PKR undergoes autophosphorylation and enzymatic activation. The dsRNA-dependent PKR activation occurs mainly during viral infections [14], and in uninfected cells PACT activates PKR in response to oxidative stress, endoplasmic reticulum (ER) stress, and serum deprivation [15, 16]. Patel and Sen cloned and identified PACT as a stress-modulated protein activator of PKR in 1998 [4]. Since then, the functional involvement of PACT-mediated PKR activation in regulating cellular response to diverse types of stress signals has been studied extensively [15, 17–19]. The functional domains of PKR and PACT have been characterized in detail and both PACT and PKR have the evolutionarily conserved dsRNA binding motifs (dsRBMs) [20–22] that also mediate the dsRNA independent protein-protein interactions between them and with other proteins that contain dsRBMs [23–25] (Figure 1). Upon binding dsRNA or PACT via the dsRBMs, PKR undergoes a conformational change which results in the autophosphorylation and activation of PKR [26, 27]. PACT is a stress-modulated activator of PKR that acts via a dsRNA-independent interaction in response to ER stress, oxidative stress, and serum deprivation [15, 16, 28]. Of the three dsRBMs present in PACT, the two amino terminal motifs dsRBM1 and 2, are critical for dsRNA binding and PACT-PKR interaction and a carboxy terminal dsRBM3 motif that does not bind dsRNA is essential for PKR activation [4, 23, 24]. Within dsRBM3, serines 246 and 287 serve as phosphorylation sites to enhance PACT-PACT homomeric interaction and the heteromeric interaction of PACT’s dsRBM3 with PKR’s catalytic domain that takes place only after PACT undergoes a stress-induced phosphorylation of serine 287 [19, 29] (Figure 2). In the absence of stress, PACT is constitutively phosphorylated on S246 [29], associates with PKR weakly [30] and is unable to activate PKR. Once phosphorylated on serine 287 in response to cellular stress, PACT’s affinity tor PACT-PACT and PACT-PKR interactions increases, thereby leading to efficient PKR association and catalytic activation [17, 30].

FIGURE 1

FIGURE 2

In last few years, several mutations have been identified (Figure 3) in PRKRA gene (OMIM: DYT16, 612067) leading to DYT-PRKRA [5–9, 31–40]. Although DYT-PRKRA was originally described to have an autosomal recessive inheritance pattern [31] but dominantly inherited variants of DYT-PRKRA have also been reported [32, 38]. Most mutations reported in DYT-PRKRA are substitution mutations that map within either the dsRBM1 and 2 or in the linker region between dsRBM2 and dsRBM3. One frameshift mutation reported in a single patient produces an early stop codon and truncates the PACT protein within dsRBM1 [32]. It is unclear if such a truncated protein would be present in the patient as no study has been conducted on patient cells. However, this truncated protein if present, will be unable to activate PKR via a direct interaction as dsRBM3 is essential for PKR activation. It is important to note that in several of DYT-PRKRA cases, developmental regression and dystonia was first noted after a febrile illness in the childhood [5–9]. This detail becomes relevant in the context of the cellular functions of PACT discussed in this review. The effects of one frameshift and several substitution mutations on PACT’s functional contribution to various cellular pathways has been studied and is discussed in the next section of this review [41–44].

FIGURE 3

The effect of DYT-PRKRA mutations on the known cellular functions of PACT

PACT impacts cellular regulation via its participation in several pathways relevant to dystonia and Figure 4 summarizes these pathways as well as how they are altered in DYT-PRKRA to affect cellular responses and function.

FIGURE 4

PKR activation and integrated stress response (ISR)

PACT-mediated PKR activation occurs in response to diverse types of stress signals [15, 17–19]. Once activated, PKR phosphorylates the α subunit of eukaryotic initiation factor 2 (eIF2α) on serine 51 and inactivates it thereby causing a general block in protein synthesis [45]. Phosphorylation of eIF2α is a central regulatory event for the ISR [46, 47], which helps cells recover appropriately from a variety of biological stresses (Figure 5). Although phosphorylation of eIF2α causes a general block in protein synthesis, it stimulates the translation of a selected few mRNAs that have upstream, short upstream open reading frames (uORFs) in their 5′ untranslated regions (5′UTRs) [48–51]. These preferentially translated mRNAs encode various stress response regulators such as the transcription factors activating transcription factor 4 (ATF4) and C/EBP-homologous protein (CHOP) that reprogram the transcriptome for adaption to stress, and trigger eIF2α dephosphorylation to promote ISR termination [52–54]. The duration and extent of the stress response is regulated by several mechanisms. For instance, ATF4 regulates the transcription of growth arrest DNA damage-inducible 34 (GADD34), which is essential for translational recovery towards survival [55, 56], and of CHOP, whose accumulation plays a pivotal role in converting the stress response from an adaptive phase to apoptosis when the ISR is overwhelmed [57–59]. The intensity, duration and kinetics of eIF2α phosphorylation as well as the nature of the downstream activated cascades determine whether a cell adapts and survives, or instead dies, in response to stress. Thus, activation of PKR by PACT if not regulated appropriately can be associated with a prolonged shutdown of protein translation, activation of caspase-8, poly ADP ribose polymerase 1(PARP1) cleavage and apoptosis [45, 60, 61].

FIGURE 5

Many DYT-PRKRA mutations have been characterized for their effects on PKR activation and ISR (Figure 6). A recessively inherited P222L mutation increases cell susceptibility to endoplasmic reticulum (ER) stress through the dysregulation of ISR signaling in patient derived lymphoblasts [42]. Furthermore, using an in vitro approach it was demonstrated that a dominantly inherited frameshift mutation expresses a truncated PACT protein that increases PACT mediated PKR activation causing an enhanced sensitivity to ER stress via dysregulation of the eIF2α signaling pathway [43]. Three recessively inherited (C77S, C213F, C213R) and two dominantly inherited DYT16 point mutations (N102S and T34S) also demonstrated a heightened capacity to form PACT-PACT homodimers in the absence of stress [44] and the lymphoblasts derived from DYT-PRKRA patients carrying C77S and C213R mutations showed a stronger binding affinity between PACT and PKR and a dysregulation of the ISR pathway. Consequently, these DYT-PRKRA patient lymphoblasts demonstrated an increase in cell susceptibility to ER stress that could be rescued in the presence of luteolin, which disrupts PACT-PKR interactions [62].

FIGURE 6

Innate immunity and inflammation

Interferons (IFNs) are antiviral cytokines that constitute a pivotal component of the body’s innate immune response against viral infections [63]. Virally infected cells produce and secrete IFNs, which prime the neighboring cells by inducing expression of hundreds of antiviral proteins even before they are infected with the virus, thus arming them with necessary defenses against a possible infection [64, 65]. The pathogen-associated molecular patterns (PAMPs) present in infected cells are sensed by pattern-recognition receptors (PRRs) of the host cells [66]. The viral non-self RNAs are sensed by host PRRs such as Retinoic acid inducible gene I (RIG-I) in the cytoplasm [67], and this is a central step to induce proinflammatory and immunoregulatory response to protect the host. PACT aids RIG-I ( ) in ligand recognition and is essential to activate a robust IFN production by binding to RIG-I’s carboxy-terminal domain and stimulating its ATPase activity to expose a caspase activation and recruitment domain (CARD) motif [68]. This activated form of RIG-I interacts with the mitochondrial antiviral signaling protein (MAVS), initiating a signaling cascade that culminates in the activation of transcription factor IRF3 to cause a robust transcriptional induction of type I interferons. Additionally, PACT also functions as a coactivator of another PRR, melanoma differentiation-associated gene 5 (MDA5) by promoting MDA5 oligomerization after dsRNA-induced activation [69] to augment IFN production (Figure 7). Laboratory of genetics and physiology 2 (LGP2) is the third and least well‐understood member of this PRR family. LGP2 modulates the function of RIG‐I and MDA5 during viral infection in a PACT dependent manner [70].

FIGURE 7

There has been a single study examining the effect of the DYT-PRKRA mutations on PACT’s ability to induce IFNs. Lymphoblasts from homozygous P222L patient as well as compound heterozygous C77S and C213R patient produced higher levels of IFN β and IFN induced genes in response to dsRNA as compared to wild type lymphoblasts [41]. Because dystonia is reported as a side effect during IFN therapy for treatment of viral infections or multiple sclerosis, it raises a possibility that DYT-PRKRA may arise from elevated levels of circulating IFNs [71, 72].Some DYT-PRKRA patients were reported to develop dystonia after a childhood febrile illness [5–9], which could have been a viral infection that may have triggered excessive or prolonged IFN production. In future, it can be tested if DYT-PRKRA patients have elevated levels of IFNs in their blood. It is relevant to also note that dystonia is one of the many symptoms Aicardi Gouetieres Syndrome (AGS), which is a rare genetic disorder classified as an interferonopathy in which a constitutive upregulation of IFN activity directly causes the disease pathology [73, 74].

RNA interference

The RNA interference (RNAi) pathway is a conserved cellular mechanism crucial for gene regulation and antiviral defense [75, 76]. Triggered by double-stranded RNA (dsRNA), the pathway involves degradation or translational repression of target messenger RNA (mRNA) with the aid of small RNA molecules like microRNAs (miRNAs) and short interfering RNAs (siRNAs). These small RNA molecules guide the large, multi-subunit RNA-induced silencing complex (RISC) to the complementary mRNA sequence/s, leading to a precise control of gene expression at a post-transcriptional level in most situations. The RNAi pathway is either initiated by miRNA biogenesis [77] that leads to expression of miRNAs or processing of long dsRNAs into siRNA duplexes by the RNase Dicer [78]. The steps downstream of generation of these small RNA molecules sequentially involve loading of miRNA or siRNA guide strand into the RISC complex containing Argonaute proteins, mRNA target recognition, and cleavage of the target mRNA by Argonaute’s endo-nucleolytic activity or a block of its translation (Figure 8) [79]. Dicer, human Argonaute 2 (hAgo2), and either human immunodeficiency virus (HIV) trans-activating RNA (TAR)-binding protein (TRBP) or PACT constitute the RISC in human cells but the exact functional role of PACT in RNAi pathway is not yet clear. Recent studies suggest that although PACT is not required for the mRNA cleavage step, it is essential for the recruitment of miRNA and siRNA to the RISC [80–85]. Dicer has two Ribonuclease III (RNase III) binding domains and one dsRBM, via which it interacts with PACT’s dsRBM3 [80]. Although TRBP has been shown to affect dicer’s cleavage activity in miRNA biogenesis pathway, PACT does not directly affect Dicer activity. Dicer, PACT and TRBP form a multimeric complex and assemble even without the involvement of pre-miRNA [80]. As there has been limited research focused on elucidating PACT’s exact functional contribution to the RNAi pathway, there remains a significant scope for investigations. There have been no studies addressing the contribution of RNAi pathway to dystonia, and it remains to be determined if the dystonia causing mutations in PACT affect either a) the generation of miRNAs that are relevant in neurons or b) the function of miRNAs to modulate gene expression important for regulation of movement coordination.

FIGURE 8

Murine Prkra gene and dystonia

Soon after cloning and characterization of human PACT as a PKR activator [4], the murine homolog of PACT was identified and termed RAX [16]. Human and murine proteins are highly homologous differing only in 6 amino acids, 4 of which are conservative changes [4, 16]. Like human PACT, murine PACT activates PKR by a direct interaction in response to cellular stress and regulates cellular fate [16, 28, 86]. A targeted disruption of murine Prkra gene demonstrated its functional contribution to craniofacial and postnatal pituitary development [87]. PACT null mouse had reduced size, severe microtia, hearing loss, reproductive issues, and diminished pituitary function. Surprisingly, these effects on the pituitary growth and function were dependent on activation of PKR and revealed that PACT functions as a PKR inhibitor in pituitary cells [88]. Such a role reversal of PACT’s function has also been observed in the context of human immunodeficiency virus (HIV) replication [89, 90]. A missense mutation S130P in the second dsRBM of murine PACT resulted in defects in ear development, growth, craniofacial development, and ovarian structure [91]. Another study reported that deletion of the entire Prkra gene in mice is embryonic lethal at a preimplantation stage of development [92]. Interestingly, the same study also reported that Drosophila carrying a mutation in loquacious, a Prkra homolog, have a severe defect in nervous system coordination or neuromuscular function resulting in significantly reduced locomotion.

The most relevant for the topic of dystonia is a recent study of a recessively inherited spontaneously arisen frameshift mutation (Figure 9), Prkra^lear-5J [93]. Mice homozygous for this mutation exhibit craniofacial developmental abnormalities, reduced body size, kinked tails, and progressive dystonia with altered gait beginning at 2 weeks of age and continuing until death at about 3 weeks of age. Some neurons in the dorsal root ganglia and the trigeminal ganglion were apoptotic, consistent with the observed neurodegenerative phenotype. Basic neurological testing on mutant mice showed that the mutant mice had an elongated step/push gait, no grasping reflex with the hind paws, a weak grasping reflex with the forepaws, kinked tails and gnarled wrists. The kinked tail and gnarled wrist phenotypes were determined to result from dystonia as the bone structure of the tail and wrists was normal. The biochemical and developmental consequences of the Prkra^lear-5J mutation were investigated recently [94]. The truncated PACT protein produced due to the frameshift mutation retained its ability to interact with PKR, however as it lacked the dsRBM3 required for PKR activation, it inhibited PKR activation. Furthermore, mice homozygous for the mutation had abnormalities in the cerebellar development as well as a severe lack of dendritic arborization of Purkinje neurons. Reduced eIF2α phosphorylation was noted in the cerebellums and Purkinje neurons of the homozygous Prkra^lear-5J mice indicating that PACT mediated regulation of PKR activity and eIF2α phosphorylation plays a role in cerebellar development and may contribute to the dystonia phenotype resulting from this Prkra mutation.

FIGURE 9

Dysregulation of ISR and eIF2α phosphorylation in dystonia

Cellular stress response and dysregulated eIF2α phosphorylation has emerged as a major area of functional convergence [3] among various monogenic dystonia types (Figure 10). Research on DYT-PRKRA established that enhanced PKR activation and dysregulated eIF2α signaling caused increased sensitivity to apoptosis in DYT-PRKRA patient cells after endoplasmic reticulum (ER) stress [42–44]. Following this initial report for DYT-PRKRA, several other dystonia types also reported dysregulated eIF2α pathway as a possible pathomechanism. DYT-TOR1A is a childhood-onset autosomal-dominant disease caused by a single amino acid deletion in the ER-resident torsinA protein. DYT-TOR1A patient cells exhibit activated ER stress response and eIF2α signaling is dysregulated [95]. Remarkably, in case of DYT-TOR1A when the eIF2α phosphorylation status was restored to normal levels, the dystonia symptoms were alleviated [96]. DYT-THAP1 is caused by mutations in THAP1 [97] and a transcriptomic analysis in neonatal mouse striatum and cerebellum indicated eIF2α signaling pathway dysregulation and the neuronal plasticity defects could be partially corrected by salubrinal, which inhibits eIF2α dephosphorylation [98]. DYT-SGCE is caused by mutations in ε-sarcoglycan (ε-SG), and PKR is upregulated in a DYT-SGCE mouse model [99]. Sporadic cervical dystonia patients have several mutations in ATF4, a downstream effector protein of the ISR response pathway [95]. Additionally, traumatic brain and spinal-cord injuries lead to injury-induced dystonia and activation of ISR and eIF2α signaling is noted in response to the injuries in animal models [100]. Finally, a growing list of dystonia genes are related to calcium physiology and may also have altered ISR and eIF2α signaling [101].

FIGURE 10

In view of the dysregulated eIF2α phosphorylation emerging as a convergent mechanism for several dystonia types, it is crucial to characterize the changes in eIF2α phosphorylation status and ultimately the regulation of ISR in each individual form of dystonia. Both increased as well as decreased eIF2α phosphorylation has been reported in various forms of monogenic dystonia. In case of DYT-PRKRA, there is a reduction in the basal eIF2α phosphorylation levels in Prkra^lear-5J mice [94], which is in contrast to the increased phosphorylation of eIF2α, heightened PKR kinase activity and enhanced sensitivity to ER stress in DYT-PRKRA patient cells [42, 44]. Additionally, increase in PKR activity and eIF2α phosphorylation is reported in DYT-EIF2AK2 (DYT33) patients carrying PKR missense variants with early onset generalized dystonia [102]. For DYT-EIF2AK2 (DYT33), PKR inactivating mutations were reported in some patients [103], thereby suggesting that a reduction in PKR activity and consequently reduced eIF2α phosphorylation may also lead to dystonia pathophysiology. The most compelling evidence of reduced eIF2α phosphorylation in dystonia comes from studies on DYT-TOR1A (DYT1), where a genome-wide RNAi screen suggested a pathogenic role of deficient eIF2α signaling [95]. The HIV protease inhibitor ritonavir, which boosts eIF2α phosphorylation corrected the mutant TOR1A protein mislocalization in vitro and when administered during an early postnatal period, showed therapeutic effects in a mouse model of DYT-TOR1A, restoring brain abnormalities and ameliorating the dystonia phenotype [96]. Additionally, there is similar eIF2α pathway impairment in patients with sporadic cervical dystonia, due to rare inactivating mutations in ATF4 [95]. There are no current or past clinical trials for drugs targeting the eIF2α pathway to treat dystonia patients and in future, a few important points should be considered for conducting such trials. Although the studies on eIF2α and dystonia are encouraging for therapeutic interventions, such manipulations must be controlled carefully. Based on the available evidence, a precise regulation of the extent and duration of eIF2α phosphorylation may be essential for optimal neuronal regulation of motor control and either a reduction or elevation of the ISR response both could lead to lack of motor coordination. Thus, any future treatments that target eIF2α phosphorylation would need to be developed with caution keeping in mind not to overcorrect the underlying pathology using drugs to either boost or inhibit eIF2α phosphorylation throughout the body under all physiological scenarios. For example, it was recently reported that the cholinergic neurons constitutively engage the ISR for dopamine modulation and skill learning [104]. Such specific use of transient eIF2α phosphorylation to regulate neuronal functions will be disturbed by drugs globally targeting eIF2α pathway and thus can have detrimental off target effects.

Discussion

Although phosphorylation of eIF2α has classically been viewed as a stress response, eIF2α phosphorylation mediated regulation of protein synthesis is utilized by neurons for mechanisms besides stress response that include behavior, memory consolidation, neuronal development, and motor control [105]. Future research using targeted mutations in specific neuronal subtypes to test the exact contribution of ISR and specifically eIF2α phosphorylation for neuronal control of muscle movement will be valuable.

In addition to the characterization of molecular pathways, it is also crucial to explore the specific regions of the brain affected by dystonia. Although dystonia is considered traditionally as a disorder of the basal ganglia [106], increasing evidence suggests that other brain areas may also play a role [107–112]. In this regard, mouse models could provide important clues to understand how alterations in the eIF2α signaling can affect neuronal function in specific regions of the brain to ultimately influence coordinated muscle movements. The dysfunction of cholinergic neurons which engage the eIF2α pathway for constitutive neuronal functionality [96] is one of the convergent mechanisms in dystonia etiology [113, 114]. Future studies can address the effects of manipulating the eIF2α pathway using several drugs currently available [98, 115–118]. It is possible to either measure physiologic dynamic changes in eIF2α phosphorylation or manipulate eIF2α signaling using genetic tools in a specific subset of neurons to understand how it influences muscle movement.

Given the functional role of PACT in the RNAi pathway, it would also be valuable to examine if there are any changes in miRNA profiles in DYT-PRKRA patient cells. Although it would be most meaningful to investigate the changes in miRNA expression profiles in induced pluripotent stem cell (iPSC) derived neurons from DYT-PRKRA patients, the miRNA profiles of patient lymphoblasts or fibroblasts can offer initial assessment if the DYT-PRKRA mutations can affect the miRNA biogenesis. Additionally, based on initial studies indicating the role of IFNs in DYT-PRKRA, it remains to be investigated if additional DYT-PRKRA mutations also enhance IFN production in response to dsRNA. Several DYT-PRKRA and DYT-EIF2AK2 patients developed dystonia symptoms after a febrile illness [5–9, 119], thus If DYT-PRKRA mutations lead to IFN production at higher levels or for a longer duration during viral infections, it can explain the neurologic regression and motor problems arising after a childhood illness. Based on such future studies the treatment for DYT-PRKRA can be significantly different based on the specific effects seen with various mutations, underscoring the urgency and importance of undertaking such basic mechanistic studies.

References

• 1

  Jinnah HA Hess EJ . Evolving concepts in the pathogenesis of dystonia. Parkinsonism Relat Disord (2018) 46(Suppl. 1):S62–S65. 10.1016/j.parkreldis.2017.08.001

  • CrossRef
  • Google Scholar

• 2

  Thomsen M Lange LM Zech M Lohmann K . Genetics and pathogenesis of dystonia. Annu Rev Pathol (2024) 19:99–131. 10.1146/annurev-pathmechdis-051122-110756

  • CrossRef
  • Google Scholar

• 3

  Gonzalez-Latapi P Marotta N Mencacci NE . Emerging and converging molecular mechanisms in dystonia. J Neural Transm (Vienna) (2021) 128(4):483–98. 10.1007/s00702-020-02290-z

  • CrossRef
  • Google Scholar

• 4

  Patel RC Sen GC . PACT, a protein activator of the interferon-induced protein kinase. PKR EMBO J (1998) 17(15):4379–90. 10.1093/emboj/17.15.4379

  • CrossRef
  • Google Scholar

• 5

  Lemmon ME Lavenstein B Applegate CD Hamosh A Tekes A Singer HS . A novel presentation of DYT 16: acute onset in infancy and association with MRI abnormalities. Mov Disord (2013) 28(14):1937–8. 10.1002/mds.25703

  • CrossRef
  • Google Scholar

• 6

  Masnada S Martinelli D Correa-Vela M Agolini E Baide-Mairena H Marcé-Grau A et al PRKRA-related disorders: bilateral striatal degeneration in addition to DYT16 spectrum. Mov Disord (2021) 36(4):1038–40. 10.1002/mds.28492

  • CrossRef
  • Google Scholar

• 7

  Bhowmick SS Raha S Bohora A . Early-onset dystonia, exacerbation with fever, and striatal signal changes: emerging phenotype of DYT-PRKRA. Neurology (2022) 99(5):206–7. 10.1212/wnl.0000000000200858

  • CrossRef
  • Google Scholar

• 8

  Pinto MJ Oliveira A Rosas MJ Massano J . Imaging evidence of nigrostriatal degeneration in DYT-PRKRA. Mov Disord Clin Pract (2020) 7(4):472–4. 10.1002/mdc3.12941

  • CrossRef
  • Google Scholar

• 9

  Kolbel H Kuechler A Strom TM Ludecke HJ Moller-Hartmann C Della-Marina A et al DYT16 mimics metabolic disease with fever associated beginning of dystonia and MRI abnormalities. Eur J Pediatr Neurol (2017) 21:e177. 10.1016/j.ejpn.2017.04.997

  • CrossRef
  • Google Scholar

• 10

  Tisch S Kumar KR . Pallidal deep brain stimulation for monogenic dystonia: the effect of gene on outcome. Front Neurol (2020) 11:630391. 10.3389/fneur.2020.630391

  • CrossRef
  • Google Scholar

• 11

  Costantini A Trevi E Pala MI Fancellu R . Thiamine and dystonia 16. BMJ Case Rep (2016) 2016–2016-216721. 10.1136/bcr-2016-216721

  • CrossRef
  • Google Scholar

• 12

  Meurs E Chong K Galabru J Thomas NS Kerr IM Williams BR et al Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell (1990) 62(2):379–90. 10.1016/0092-8674(90)90374-n

  • CrossRef
  • Google Scholar

• 13

  Galabru J Hovanessian A . Autophosphorylation of the protein kinase dependent on double-stranded RNA. J Biol Chem (1987) 262(32):15538–44. 10.1016/s0021-9258(18)47759-9

  • CrossRef
  • Google Scholar

• 14

  Garcia MA Meurs EF Esteban M . The dsRNA protein kinase PKR: virus and cell control. Biochimie (2007) 89(6-7):799–811. 10.1016/j.biochi.2007.03.001

  • CrossRef
  • Google Scholar

• 15

  Patel CV Handy I Goldsmith T Patel RC . PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase. PKR J Biol Chem (2000) 275(48):37993–8. 10.1074/jbc.M004762200

  • CrossRef
  • Google Scholar

• 16

  Ito T Yang M May WS . RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem (1999) 274(22):15427–32. 10.1074/jbc.274.22.15427

  • CrossRef
  • Google Scholar

• 17

  Singh M Castillo D Patel CV Patel RC . Stress-induced phosphorylation of PACT reduces its interaction with TRBP and leads to PKR activation. Biochemistry (2011) 50(21):4550–60. 10.1021/bi200104h

  • CrossRef
  • Google Scholar

• 18

  Singh M Fowlkes V Handy I Patel CV Patel RC . Essential role of PACT-mediated PKR activation in tunicamycin-induced apoptosis. J Mol Biol (2009) 385(2):457–68. 10.1016/j.jmb.2008.10.068

  • CrossRef
  • Google Scholar

• 19

  Singh M Patel RC . Increased interaction between PACT molecules in response to stress signals is required for PKR activation. J Cell Biochem (2012) 113(8):2754–64. 10.1002/jcb.24152

  • CrossRef
  • Google Scholar

• 20

  Patel RC Sen GC . Identification of the double-stranded RNA-binding domain of the human interferon-inducible protein kinase. J Biol Chem (1992) 267(11):7671–6. 10.1016/s0021-9258(18)42567-7

  • CrossRef
  • Google Scholar

• 21

  Feng GS Chong K Kumar A Williams BR . Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase. Proc Natl Acad Sci U S A. (1992) 89(12):5447–51. 10.1073/pnas.89.12.5447

  • CrossRef
  • Google Scholar

• 22

  Green SR Mathews MB . Two RNA-binding motifs in the double-stranded RNA-activated protein kinase, DAI. Genes Dev. (1992) 6(12B):2478–90. 10.1101/gad.6.12b.2478

  • CrossRef
  • Google Scholar

• 23

  Huang X Hutchins B Patel RC . The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR). Biochem J (2002) 366(Pt 1):175–86. 10.1042/BJ20020204

  • CrossRef
  • Google Scholar

• 24

  Peters GA Hartmann R Qin J Sen GC . Modular structure of PACT: distinct domains for binding and activating PKR. Mol Cell Biol (2001) 21(6):1908–20. 10.1128/MCB.21.6.1908-1920.2001

  • CrossRef
  • Google Scholar

• 25

  Chang KY Ramos A . The double-stranded RNA-binding motif, a versatile macromolecular docking platform. FEBS J (2005) 272(9):2109–17. 10.1111/j.1742-4658.2005.04652.x

  • CrossRef
  • Google Scholar

• 26

  Cole JL . Activation of PKR: an open and shut case?Trends Biochem Sci (2007) 32(2):57–62. 10.1016/j.tibs.2006.12.003

  • CrossRef
  • Google Scholar

• 27

  Nanduri S Carpick BW Yang Y Williams BR Qin J . Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J (1998) 17(18):5458–65. 10.1093/emboj/17.18.5458

  • CrossRef
  • Google Scholar

• 28

  Bennett RL Blalock WL May WS . Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition. J Biol Chem (2004) 279(41):42687–93. 10.1074/jbc.M403321200

  • CrossRef
  • Google Scholar

• 29

  Peters GA Li S Sen GC . Phosphorylation of specific serine residues in the PKR activation domain of PACT is essential for its ability to mediate apoptosis. J Biol Chem (2006) 281(46):35129–36. 10.1074/jbc.M607714200

  • CrossRef
  • Google Scholar

• 30

  Daher A Laraki G Singh M Melendez-Pena CE Bannwarth S Peters AH et al TRBP control of PACT-induced phosphorylation of protein kinase R is reversed by stress. Mol Cell Biol (2009) 29(1):254–65. 10.1128/MCB.01030-08

  • CrossRef
  • Google Scholar

• 31

  Camargos S Scholz S Simon-Sanchez J Paisan-Ruiz C Lewis P Hernandez D et al DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 7(3):207–15. 10.1016/S1474-4422(08)70022-X

  • CrossRef
  • Google Scholar

• 32

  Seibler P Djarmati A Langpap B Hagenah J Schmidt A Bruggemann N et al A heterozygous frameshift mutation in PRKRA (DYT16) associated with generalised dystonia in a German patient. Lancet Neurol (2008) 7(5):380–1. 10.1016/S1474-4422(08)70075-9

  • CrossRef
  • Google Scholar

• 33

  Najmabadi H Hu H Garshasbi M Zemojtel T Abedini SS Chen W et al Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature (2011) 478(7367):57–63. 10.1038/nature10423

  • CrossRef
  • Google Scholar

• 34

  Camargos S Lees AJ Singleton A Cardoso F . DYT16: the original cases. J Neurol Neurosurg Psychiatry (2012) 83(10):1012–4. 10.1136/jnnp-2012-302841

  • CrossRef
  • Google Scholar

• 35

  de Carvalho Aguiar P Borges V Ferraz HB Ozelius LJ . Novel compound heterozygous mutations in PRKRA cause pure dystonia. Mov Disord (2015) 30(6):877–8. 10.1002/mds.26175

  • CrossRef
  • Google Scholar

• 36

  Dos Santos CO da Silva-Junior FP Puga RD Barbosa ER Azevedo Silva SMC Borges V et al The prevalence of PRKRA mutations in idiopathic dystonia. Parkinsonism Relat Disord (2018) 48:93–6. 10.1016/j.parkreldis.2017.12.015

  • CrossRef
  • Google Scholar

• 37

  Quadri M Olgiati S Sensi M Gualandi F Groppo E Rispoli V et al PRKRA mutation causing early-onset generalized dystonia-parkinsonism (DYT16) in an Italian family. Mov Disord (2016) 31(5):765–7. 10.1002/mds.26583

  • CrossRef
  • Google Scholar

• 38

  Zech M Castrop F Schormair B Jochim A Wieland T Gross N et al DYT16 revisited: exome sequencing identifies PRKRA mutations in a European dystonia family. Mov Disord (2014) 29(12):1504–10. 10.1002/mds.25981

  • CrossRef
  • Google Scholar

• 39

  Lange LM Junker J Loens S Baumann H Olschewski L Schaake S et al Genotype-phenotype relations for isolated dystonia genes: MDSGene systematic review. Mov Disord (2021) 36(5):1086–103. 10.1002/mds.28485

  • CrossRef
  • Google Scholar

• 40

  Atasu B Simón-Sánchez J Hanagasi H Bilgic B Hauser AK Guven G et al Dissecting genetic architecture of rare dystonia: genetic, molecular and clinical insights. J Med Genet (2024) 61(5):443–51. 10.1136/jmg-2022-109099

  • CrossRef
  • Google Scholar

• 41

  Vaughn LS Frederick K Burnett SB Sharma N Bragg DC Camargos S et al DYT-PRKRA mutation P222L enhances PACT's stimulatory activity on type I interferon induction. Biomolecules (2022) 12(5):713. 10.3390/biom12050713

  • CrossRef
  • Google Scholar

• 42

  Vaughn LS Bragg DC Sharma N Camargos S Cardoso F Patel RC . Altered activation of protein kinase PKR and enhanced apoptosis in dystonia cells carrying a mutation in PKR activator protein PACT. J Biol Chem (2015) 290(37):22543–57. 10.1074/jbc.M115.669408

  • CrossRef
  • Google Scholar

• 43

  Burnett SB Vaughn LS Strom JM Francois A Patel RC . A truncated PACT protein resulting from a frameshift mutation reported in movement disorder DYT16 triggers caspase activation and apoptosis. J Cell Biochem (2019) 120(11):19004–18. 10.1002/jcb.29223

  • CrossRef
  • Google Scholar

• 44

  Burnett SB Vaughn LS Sharma N Kulkarni R Patel RC . Dystonia 16 (DYT16) mutations in PACT cause dysregulated PKR activation and eIF2α signaling leading to a compromised stress response. Neurobiol Dis (2020) 146:105135. 10.1016/j.nbd.2020.105135

  • CrossRef
  • Google Scholar

• 45

  Sadler AJ Williams BR . Structure and function of the protein kinase R. Curr Top Microbiol Immunol (2007) 316:253–92. 10.1007/978-3-540-71329-6_13

  • CrossRef
  • Google Scholar

• 46

  Brostrom CO Prostko CR Kaufman RJ Brostrom MA . Inhibition of translational initiation by activators of the glucose-regulated stress protein and heat shock protein stress response systems. Role of the interferon-inducible double-stranded RNA-activated eukaryotic initiation factor 2alpha kinase. J Biol Chem (1996) 271(40):24995–5002. 10.1074/jbc.271.40.24995

  • CrossRef
  • Google Scholar

• 47

  Pakos-Zebrucka K Koryga I Mnich K Ljujic M Samali A Gorman AM . The integrated stress response. EMBO Rep (2016) 17(10):1374–95. 10.15252/embr.201642195

  • CrossRef
  • Google Scholar

• 48

  Starck SR Tsai JC Chen K Shodiya M Wang L Yahiro K et al Translation from the 5' untranslated region shapes the integrated stress response. Science (2016) 351(6272):aad3867. 10.1126/science.aad3867

  • CrossRef
  • Google Scholar

• 49

  Young SK Wek RC . Upstream open reading frames differentially regulate gene-specific translation in the integrated stress response. J Biol Chem (2016) 291(33):16927–35. 10.1074/jbc.R116.733899

  • CrossRef
  • Google Scholar

• 50

  Ron D . Translational control in the endoplasmic reticulum stress response. J Clin Invest (2002) 110(10):1383–8. 10.1172/JCI16784

  • CrossRef
  • Google Scholar

• 51

  Andreev DE O'Connor PB Fahey C Kenny EM Terenin IM Dmitriev SE et al Translation of 5' leaders is pervasive in genes resistant to eIF2 repression. Elife (2015) 4:e03971. 10.7554/eLife.03971

  • CrossRef
  • Google Scholar

• 52

  Lee YY Cevallos RC Jan E . An upstream open reading frame regulates translation of GADD34 during cellular stresses that induce eIF2alpha phosphorylation. J Biol Chem (2009) 284(11):6661–73. 10.1074/jbc.M806735200

  • CrossRef
  • Google Scholar

• 53

  Palam LR Baird TD Wek RC . Phosphorylation of eIF2 facilitates ribosomal bypass of an inhibitory upstream ORF to enhance CHOP translation. J Biol Chem (2011) 286(13):10939–49. 10.1074/jbc.M110.216093

  • CrossRef
  • Google Scholar

• 54

  Vattem KM Staschke KA Wek RC . Mechanism of activation of the double-stranded-RNA-dependent protein kinase, PKR: role of dimerization and cellular localization in the stimulation of PKR phosphorylation of eukaryotic initiation factor-2 (eIF2). Eur J Biochem (2001) 268(13):3674–84. 10.1046/j.1432-1327.2001.02273.x

  • CrossRef
  • Google Scholar

• 55

  Kojima E Takeuchi A Haneda M Yagi A Hasegawa T Yamaki K et al The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress: elucidation by GADD34-deficient mice. FASEB J (2003) 17(11):1573–5. 10.1096/fj.02-1184fje

  • CrossRef
  • Google Scholar

• 56

  Ma Y Hendershot LM . Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem (2003) 278(37):34864–73. 10.1074/jbc.M301107200

  • CrossRef
  • Google Scholar

• 57

  Galehdar Z Swan P Fuerth B Callaghan SM Park DS Cregan SP . Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA. J Neurosci (2010) 30(50):16938–48. 10.1523/jneurosci.1598-10.2010

  • CrossRef
  • Google Scholar

• 58

  Li Y Guo Y Tang J Jiang J Chen Z . New insights into the roles of CHOP-induced apoptosis in ER stress. Acta Biochim Biophys Sin (Shanghai) (2014) 46(8):629–40. 10.1093/abbs/gmu048

  • CrossRef
  • Google Scholar

• 59

  Marciniak SJ Ron D . Endoplasmic reticulum stress signaling in disease. Physiol Rev (2006) 86(4):1133–49. 10.1152/physrev.00015.2006

  • CrossRef
  • Google Scholar

• 60

  Sen GC Peters GA . Viral stress-inducible genes. Adv Virus Res (2007) 70:233–63. 10.1016/S0065-3527(07)70006-4

  • CrossRef
  • Google Scholar

• 61

  Williams BR . Signal integration via PKR. Sci STKE (2001) 2001(89):RE2. 10.1126/stke.2001.89.re2

  • CrossRef
  • Google Scholar

• 62

  Frederick K Patel RC . Luteolin protects DYT-PRKRA cells from apoptosis by suppressing PKR activation. Front Pharmacol (2023) 14:1118725. 10.3389/fphar.2023.1118725

  • CrossRef
  • Google Scholar

• 63

  Dalskov L Gad HH Hartmann R . Viral recognition and the antiviral interferon response. EMBO J (2023) 42(14):e112907. 10.15252/embj.2022112907

  • CrossRef
  • Google Scholar

• 64

  Ivashkiv LB Donlin LT . Regulation of type I interferon responses. Nat Rev Immunol (2014) 14(1):36–49. 10.1038/nri3581

  • CrossRef
  • Google Scholar

• 65

  Babadei O Strobl B Müller M Decker T . Transcriptional control of interferon-stimulated genes. J Biol Chem (2024) 300(10):107771. 10.1016/j.jbc.2024.107771

  • CrossRef
  • Google Scholar

• 66

  Gewaid H Bowie AG . Regulation of type I and type III interferon induction in response to pathogen sensing. Curr Opin Immunol (2024) 87:102424. 10.1016/j.coi.2024.102424

  • CrossRef
  • Google Scholar

• 67

  Yoneyama M Kikuchi M Natsukawa T Shinobu N Imaizumi T Miyagishi M et al The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 5(7):730–7. 10.1038/ni1087

  • CrossRef
  • Google Scholar

• 68

  Kok KH Lui PY Ng MH Siu KL Au SW Jin DY . The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe (2011) 9(4):299–309. 10.1016/j.chom.2011.03.007

  • CrossRef
  • Google Scholar

• 69

  Lui PY Wong LR Ho TH Au SWN Chan CP Kok KH et al PACT facilitates RNA-induced activation of MDA5 by promoting MDA5 oligomerization. J Immunol (2017) 199(5):1846–55. 10.4049/jimmunol.1601493

  • CrossRef
  • Google Scholar

• 70

  Sanchez David RY Combredet C Najburg V Millot GA Beauclair G Schwikowski B et al LGP2 binds to PACT to regulate RIG-I- and MDA5-mediated antiviral responses. Sci Signal (2019) 12(601):eaar3993. 10.1126/scisignal.aar3993

  • CrossRef
  • Google Scholar

• 71

  Atasoy N Ustundag Y Konuk N Atik L . Acute dystonia during pegylated interferon alpha therapy in a case with chronic hepatitis B infection. Clin Neuropharmacol (2004) 27(3):105–7. 10.1097/00002826-200405000-00002

  • CrossRef
  • Google Scholar

• 72

  Quarantini LC Miranda-Scippa A Parana R Sampaio AS Bressan RA . Acute dystonia after injection of pegylated interferon alpha-2b. Mov Disord (2007) 22(5):747–8. 10.1002/mds.21302

  • CrossRef
  • Google Scholar

• 73

  Rice GI Kasher PR Forte GM Mannion NM Greenwood SM Szynkiewicz M et al Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet (2012) 44(11):1243–8. 10.1038/ng.2414

  • CrossRef
  • Google Scholar

• 74

  Livingston JH Lin JP Dale RC Gill D Brogan P Munnich A et al A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet (2014) 51(2):76–82. 10.1136/jmedgenet-2013-102038

  • CrossRef
  • Google Scholar

• 75

  Wilson RC Doudna JA . Molecular mechanisms of RNA interference. Annu Rev Biophys (2013) 42:217–39. 10.1146/annurev-biophys-083012-130404

  • CrossRef
  • Google Scholar

• 76

  Jinek M Doudna JA . A three-dimensional view of the molecular machinery of RNA interference. Nature (2009) 457(7228):405–12. 10.1038/nature07755

  • CrossRef
  • Google Scholar

• 77

  Shang R Lee S Senavirathne G Lai EC . microRNAs in action: biogenesis, function and regulation. Nat Rev Genet (2023) 24(12):816–33. 10.1038/s41576-023-00611-y

  • CrossRef
  • Google Scholar

• 78

  Zapletal D Kubicek K Svoboda P Stefl R . Dicer structure and function: conserved and evolving features. EMBO Rep (2023) 24(7):e57215. 10.15252/embr.202357215

  • CrossRef
  • Google Scholar

• 79

  Olina AV Kulbachinskiy AV Aravin AA Esyunina DM . Argonaute proteins and mechanisms of RNA interference in eukaryotes and prokaryotes. Biochemistry (Mosc). (2018) 83(5):483–97. 10.1134/s0006297918050024

  • CrossRef
  • Google Scholar

• 80

  Lee Y Hur I Park SY Kim YK Suh MR Kim VN . The role of PACT in the RNA silencing pathway. EMBO J (2006) 25(3):522–32. 10.1038/sj.emboj.7600942

  • CrossRef
  • Google Scholar

• 81

  Noland CL Doudna JA . Multiple sensors ensure guide strand selection in human RNAi pathways. RNA (2013) 19(5):639–48. 10.1261/rna.037424.112

  • CrossRef
  • Google Scholar

• 82

  Takahashi T Miyakawa T Zenno S Nishi K Tanokura M Ui-Tei K . Distinguishable in vitro binding mode of monomeric TRBP and dimeric PACT with siRNA. PLoS One (2013) 8(5):e63434. 10.1371/journal.pone.0063434

  • CrossRef
  • Google Scholar

• 83

  Lee HY Zhou K Smith AM Noland CL Doudna JA . Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic Acids Res (2013) 41(13):6568–76. 10.1093/nar/gkt361

  • CrossRef
  • Google Scholar

• 84

  Wilson RC Tambe A Kidwell MA Noland CL Schneider CP Doudna JA . Dicer-TRBP complex formation ensures accurate mammalian MicroRNA biogenesis. Mol Cell (2015) 57(3):397–407. 10.1016/j.molcel.2014.11.030

  • CrossRef
  • Google Scholar

• 85

  Heyam A Lagos D Plevin M . Dissecting the roles of TRBP and PACT in double-stranded RNA recognition and processing of noncoding RNAs. Wiley Interdiscip Rev RNA (2015) 6(3):271–89. 10.1002/wrna.1272

  • CrossRef
  • Google Scholar

• 86

  Bennett RL Blalock WL Abtahi DM Pan Y Moyer SA May WS . RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood (2006) 108(3):821–9. 10.1182/blood-2005-11-006817

  • CrossRef
  • Google Scholar

• 87

  Rowe TM Rizzi M Hirose K Peters GA Sen GC . A role of the double-stranded RNA-binding protein PACT in mouse ear development and hearing. Proc Natl Acad Sci U S A. (2006) 103(15):5823–8. 10.1073/pnas.0601287103

  • CrossRef
  • Google Scholar

• 88

  Dickerman BK White CL Kessler PM Sadler AJ Williams BR Sen GC . The protein activator of protein kinase R, PACT/RAX, negatively regulates protein kinase R during mouse anterior pituitary development. FEBS J (2015) 282(24):4766–81. 10.1111/febs.13533

  • CrossRef
  • Google Scholar

• 89

  Clerzius G Shaw E Daher A Burugu S Gelinas JF Ear T et al The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication. Retrovirology (2013) 10:96. 10.1186/1742-4690-10-96

  • CrossRef
  • Google Scholar

• 90

  Chukwurah E Handy I Patel RC . ADAR1 and PACT contribute to efficient translation of transcripts containing HIV-1 trans-activating response (TAR) element. Biochem J (2017) 474(7):1241–57. 10.1042/bcj20160964

  • CrossRef
  • Google Scholar

• 91

  Dickerman BK White CL Chevalier C Nalesso V Charles C Fouchecourt S et al Missense mutation in the second RNA binding domain reveals a role for Prkra (PACT/RAX) during skull development. PLoS One (2011) 6(12):e28537. 10.1371/journal.pone.0028537

  • CrossRef
  • Google Scholar

• 92

  Bennett RL Blalock WL Choi EJ Lee YJ Zhang Y Zhou L et al RAX is required for fly neuronal development and mouse embryogenesis. Mech Dev (2008) 125(9-10):777–85. 10.1016/j.mod.2008.06.009

  • CrossRef
  • Google Scholar

• 93

  Palmer K Fairfield H Borgeia S Curtain M Hassan MG Dionne L et al Discovery and characterization of spontaneous mouse models of craniofacial dysmorphology. Dev Biol (2016) 415(2):216–27. 10.1016/j.ydbio.2015.07.023

  • CrossRef
  • Google Scholar

• 94

  Burnett SB Culver AM Simon TA Rowson T Frederick K Palmer K et al Mutation in Prkra results in cerebellar abnormality and reduced eIF2α phosphorylation in a model of DYT-PRKRA. Dis Model Mech (2024) 17(11):dmm050929. 10.1242/dmm.050929

  • CrossRef
  • Google Scholar

• 95

  Rittiner JE Caffall ZF Hernandez-Martinez R Sanderson SM Pearson JL Tsukayama KK et al Functional genomic analyses of mendelian and sporadic disease identify impaired eIF2alpha signaling as a generalizable mechanism for dystonia. Neuron (2016) 92(6):1238–51. 10.1016/j.neuron.2016.11.012

  • CrossRef
  • Google Scholar

• 96

  Caffall ZF Wilkes BJ Hernández-Martinez R Rittiner JE Fox JT Wan KK et al The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia. Sci Transl Med (2021) 13(607):eabd3904. 10.1126/scitranslmed.abd3904

  • CrossRef
  • Google Scholar

• 97

  Zakirova Z Fanutza T Bonet J Readhead B Zhang W Yi Z et al Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions. PLoS Genet (2018) 14(1):e1007169. 10.1371/journal.pgen.1007169

  • CrossRef
  • Google Scholar

• 98

  Boyce M Bryant KF Jousse C Long K Harding HP Scheuner D et al A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science (2005) 307(5711):935–9. 10.1126/science.1101902

  • CrossRef
  • Google Scholar

• 99

  Xiao J Vemula SR Xue Y Khan MM Carlisle FA Waite AJ et al Role of major and brain-specific Sgce isoforms in the pathogenesis of myoclonus-dystonia syndrome. Neurobiol Dis (2017) 98:52–65. 10.1016/j.nbd.2016.11.003

  • CrossRef
  • Google Scholar

• 100

  Chou A Krukowski K Jopson T Zhu PJ Costa-Mattioli M Walter P et al Inhibition of the integrated stress response reverses cognitive deficits after traumatic brain injury. Proc Natl Acad Sci U S A (2017) 114(31):E6420-E6426–e6. 10.1073/pnas.1707661114

  • CrossRef
  • Google Scholar

• 101

  Jinnah HA Sun YV . Dystonia genes and their biological pathways. Neurobiol Dis (2019) 129:159–68. 10.1016/j.nbd.2019.05.014

  • CrossRef
  • Google Scholar

• 102

  Kuipers DJS Mandemakers W Lu CS Olgiati S Breedveld GJ Fevga C et al EIF2AK2 missense variants associated with early onset generalized dystonia. Ann Neurol (2021) 89(3):485–97. 10.1002/ana.25973

  • CrossRef
  • Google Scholar

• 103

  Mao D Reuter CM Ruzhnikov MRZ Beck AE Farrow EG Emrick LT et al De novo EIF2AK1 and EIF2AK2 variants are associated with developmental delay, leukoencephalopathy, and neurologic decompensation. Am J Hum Genet (2020) 106(4):570–83. 10.1016/j.ajhg.2020.02.016

  • CrossRef
  • Google Scholar

• 104

  Helseth AR Hernandez-Martinez R Hall VL Oliver ML Turner BD Caffall ZF et al Cholinergic neurons constitutively engage the ISR for dopamine modulation and skill learning in mice. Science (2021) 372(6540):eabe1931. 10.1126/science.abe1931

  • CrossRef
  • Google Scholar

• 105

  Bellato HM Hajj GN . Translational control by eIF2α in neurons: beyond the stress response. Cytoskeleton (Hoboken) (2016) 73(10):551–65. 10.1002/cm.21294

  • CrossRef
  • Google Scholar

• 106

  Mink JW . The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol (2003) 60(10):1365–8. 10.1001/archneur.60.10.1365

  • CrossRef
  • Google Scholar

• 107

  Jinnah HA Neychev V Hess EJ . The anatomical basis for dystonia: the motor network model. Tremor Other Hyperkinet Mov (N Y) (2017) 7:506. 10.7916/D8V69X3S

  • CrossRef
  • Google Scholar

• 108

  Shakkottai VG Batla A Bhatia K Dauer WT Dresel C Niethammer M et al Current opinions and areas of consensus on the role of the cerebellum in dystonia. Cerebellum (2017) 16(2):577–94. 10.1007/s12311-016-0825-6

  • CrossRef
  • Google Scholar

• 109

  Prudente CN Hess EJ Jinnah HA . Dystonia as a network disorder: what is the role of the cerebellum?Neuroscience (2014) 260:23–35. 10.1016/j.neuroscience.2013.11.062

  • CrossRef
  • Google Scholar

• 110

  Neychev VK Fan X Mitev VI Hess EJ Jinnah HA . The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain (2008) 131(Pt 9):2499–509. 10.1093/brain/awn168

  • CrossRef
  • Google Scholar

• 111

  Mahajan A Gupta P Jacobs J Marsili L Sturchio A Jinnah HA et al Impaired saccade adaptation in tremor-dominant cervical dystonia-evidence for maladaptive cerebellum. Cerebellum (2021) 20(5):678–86. 10.1007/s12311-020-01104-y

  • CrossRef
  • Google Scholar

• 112

  Brown AM van der Heijden ME Jinnah HA Sillitoe RV . Cerebellar dysfunction as a source of dystonic phenotypes in mice. Cerebellum (2023) 22(4):719–29. 10.1007/s12311-022-01441-0

  • CrossRef
  • Google Scholar

• 113

  Eskow Jaunarajs KL Scarduzio M Ehrlich ME McMahon LL Standaert DG . Diverse mechanisms lead to common dysfunction of striatal cholinergic interneurons in distinct genetic mouse models of dystonia. J Neurosci (2019) 39(36):7195–205. 10.1523/jneurosci.0407-19.2019

  • CrossRef
  • Google Scholar

• 114

  Eskow Jaunarajs KL Bonsi P Chesselet MF Standaert DG Pisani A . Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Prog Neurobiol (2015) 127-128:91–107. 10.1016/j.pneurobio.2015.02.002

  • CrossRef
  • Google Scholar

• 115

  Sidrauski C McGeachy AM Ingolia NT Walter P . The small molecule ISRIB reverses the effects of eIF2α phosphorylation on translation and stress granule assembly. Elife (2015) 4:e05033. 10.7554/eLife.05033

  • CrossRef
  • Google Scholar

• 116

  Sekine Y Zyryanova A Crespillo-Casado A Fischer PM Harding HP Ron D . Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound. Science (2015) 348(6238):1027–30. 10.1126/science.aaa6986

  • CrossRef
  • Google Scholar

• 117

  Carrara M Sigurdardottir A Bertolotti A . Decoding the selectivity of eIF2alpha holophosphatases and PPP1R15A inhibitors. Nat Struct Mol Biol (2017) 24(9):708–16. 10.1038/nsmb.3443

  • CrossRef
  • Google Scholar

• 118

  Fullwood MJ Zhou W Shenolikar S . Targeting phosphorylation of eukaryotic initiation factor-2α to treat human disease. Prog Mol Biol Transl Sci (2012) 106:75–106. 10.1016/b978-0-12-396456-4.00005-5

  • CrossRef
  • Google Scholar

• 119

  Waller SE Morales-Briceño H Williams L Mohammad SS Fellner A Kumar KR et al Possible EIF2AK2-associated stress-related neurological decompensation with combined dystonia and striatal lesions. Mov Disord Clin Pract (2022) 9(2):240–4. 10.1002/mdc3.13384

  • CrossRef
  • Google Scholar